APA (7th ed.) Citation

Janssen, J. C., van Dijk, B., de Joode, K., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., . . . Oomen-de Hoop, E. (2024). Safe Stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol. BMC Cancer, 24(1), 1. https://doi.org/10.1186/s12885-024-12336-0

Chicago Style (17th ed.) Citation

Janssen, J. C., et al. "Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab upon Achieving a Complete or Partial Response in Patients with Irresectable Stage III or Metastatic Melanoma Treated with First-line Ipilimumab-nivolumab – Study Protocol." BMC Cancer 24, no. 1 (2024): 1. https://doi.org/10.1186/s12885-024-12336-0.

MLA (9th ed.) Citation

Janssen, J. C., et al. "Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab upon Achieving a Complete or Partial Response in Patients with Irresectable Stage III or Metastatic Melanoma Treated with First-line Ipilimumab-nivolumab – Study Protocol." BMC Cancer, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12885-024-12336-0.